PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

This is an interventional treatment trial for Small Cell Lung Cancer focused on measuring PARP Inhibitor, Chemotherapy, DDR Inhibitor Read More

• INCLUSION CRITERIA:

• Subjects with:

  • histologically confirmed solid tumors (Phase I), OR
  • histologically or cytologically confirmed SCLC (Phase II), OR
  • histologically or cytologically confirmed extra-pulmonary small cell carcinomas (Phase II).
• Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of PLX038 in combination with rucaparib in participants <18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.
• Subjects must have progressed on or after standard first-line systemic chemotherapy and have no effective treatment options.
• Participants must have disease that is not amenable to potentially curative resection.
• Participants must have measurable disease per RECIST 1.1.
• Participants with asymptomatic brain metastases and treated brain metastases are eligible.
• ECOG performance status less than or equal to 2.

• Adequate hematological function defined by:

  • white blood cell (WBC) count greater than or equal to 3 x 10^9/L,
  • absolute neutrophil count (ANC) greater than or equal to 1.5 x10^9/L,
  • platelet count greater than or equal to 100 x 10^9/L,
  • Hgb greater than or equal to 9 g/ dL

• Adequate hepatic function defined by:

  • a total bilirubin level less than or equal to 1.5 x ULN,
  • an AST level less than or equal to 2.5xULN, (less than or equal to 5X ULN if liver metastasis)
  • an ALT level less than or equal to 2.5 xULN, (less than or equal to 5X ULN if liver metastasis).

• Adequate renal function defined by:

  • Creatinine OR Measured or calculated creatinine clearance (CrCl) (eGFR may also be used in place of CrCl): < 1.5x institution upper limit of normal OR greater than or equal to 45 mL/min/1.73 m^2 for participant with creatinine levels greater than or equal to 1.5 X institutional ULN.

Note: Creatinine clearance (CrCl) or eGFR should be calculated per institutional standard.

• The effects of the study treatment on the developing human fetus are unknown; thus, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study treatment and up to 6 months after the last dose of the study drug (s). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
• Subjects must be able to understand and willing to sign a written informed consent document.

EXCLUSION CRITERIA:

• Participants who are receiving any other investigational agents.
• Systemic anti-cancer treatment or major surgery within 2 weeks prior to enrollment.
• Radiotherapy within 24 hours prior to enrollment.
• Participants who require treatment with strong inhibitors or inducers of CYP3A or with UGT1A1 inhibitors during the planned period of investigational treatment with PLX038.
• Participants with known Gilbert s syndrome.
• Participants homozygous for the UGT1A1*28 variant allele with severely reduced UGT1A1 activity.
• Participants with known HIV, HCV, HBV status on antiviral drugs are excluded due to the absence of previous experience with concurrent use of antiviral medications and the investigational drug product to be evaluated in the current study and possible for adverse pharmacokinetic and/or pharmacodynamic interactions.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to PLX038 or rucaparib.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that may impair the participants tolerance of study treatments.
• Pregnant women are excluded from this study because PEGSN38 and rucaparib potential for teratogenic or abortifacient effects are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with PEGSN38 and rucaparib, breastfeeding should be discontinued if the mother is treated with study drugs.